fashion -WSS

fashion

author：comprehensive 2025-08-20 09:42:28 - browse：74881

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Erich Jarvis studies song birds to learn about human stuttering

WSS

A disappointing year of Humira biosimilars

Diabetes management: Digital health tools fall short, study says

Private equity deals in Medicare Advantage declines

What should King Charles tell the public about his cancer?

Chinese researcher claims birth of first gene

Biden report: The neurospychology of memory and aging

hotspot

fashion

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

This gene therapy has record $4.25 million price. It's saved children.

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Illumina, CRISPR, Regeneron

The high cost of giving birth even with insurance

Testing GLP

Hepatitis C has a cure — but many Americans still lack access to it

How digital tools helped lower hypertension in marginalized patients

Apple is now the first public company to be valued at $3 trillion

What should King Charles tell the public about his cancer?

Wikipedia

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

This gene therapy has record $4.25 million price. It's saved children.

Surgeons perform first xenotransplant using CRISPR'd pig kidney

6 surprising facts about sugar

Medicare Advantage insurers pressure Biden for bigger payments

Texas board proposes rules on abortion law emergency exemption

hotspot

explore

knowledge

hotspot